业绩表现强劲

Financial Performance - In Q3 2026, Daiichi Sankyo reported a revenue increase of 15.1% year-on-year to ¥558 billion, and a net profit increase of 39.9% to ¥87 billion, both exceeding Bloomberg consensus expectations[5] - Sales of Enhertu grew by 31.7% year-on-year to ¥188 billion, driven by its recent approval for first-line treatment of breast cancer[5] - Datroway sales increased by 52.9% quarter-on-quarter to ¥15.9 billion, prompting management to raise the full-year sales guidance for Datroway from ¥37.8 billion to ¥47 billion[5] Key Developments - The release of key data from four major Phase III trials for Datroway has been postponed, with the Avanzar trial results now expected in the second half of 2026[6] - The company is shifting towards biomarker-driven research, as evidenced by the recent launch of the Tropion-Lung17 trial, which uses TROP2 standardized membrane ratio (NMR) for patient selection[6] Risks and Challenges - Despite the efficacy of drugs like Enhertu, toxicity concerns remain, with potential FDA black box warnings limiting its use in broader patient populations[8] - The reliance on a few key products like Enhertu may pose long-term risks if clinical or regulatory outcomes do not meet market expectations[8] - The COVID-19 pandemic may impact sales due to patients avoiding hospitals, affecting the penetration of new products[9]